Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2010
Total revenues for the third quarter and first nine months of 2010 were $74.0 million and $182.9 million, respectively. Net income for the third quarter and first nine months of 2010 was $13.1...
Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders...
Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010
Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for third quarter 2010 on Thursday November 4, 2010, after market...
Emergent BioSolutions Launches Singapore Operations
Emergent BioSolutions Inc. (NYSE:EBS), a U.S.-based developer and manufacturer of vaccines and antibody therapies, today launched its Singapore operations. The opening event included a ceremonial...
Emergent BioSolutions Receives Fast Track Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalational Anthrax
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast...
Emergent BioSolutions to Participate in October 2010 Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be participating in the following investor conferences in October...
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the...
Emergent BioSolutions Announces Commencement of Phase I Clinical Trial for Monoclonal Antibody to Treat Inhalational Anthrax
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent’s...
Emergent BioSolutions Announces Early Termination of HSR Waiting Period for Its Acquisition of Trubion Pharmaceuticals
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino...
Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute...
Emergent BioSolutions Announces Appointment of John E. Niederhuber, M.D. to the Company’s Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's Board of Directors appointed John E. Niederhuber, M.D. as a Class III Director for a two-year term that will expire at the...
Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
Emergent BioSolutions Inc. (NYSE:EBS) today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium...